Amalgamated Bank’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Amalgamated Bank’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,917	Closed	-$528K	–	3197
2023 Q1	$528K	Sell	4,917 -810	-14%	-$93.2K	﹤0.01%	1400
2022 Q4	$630K	Buy	5,727 +775	+16%	+$50.3K	0.01%	1356
2022 Q3	$292K	Buy	4,952 +298	+6%	+$13.6K	﹤0.01%	1691
2022 Q2	$131K	Buy	4,654 +872	+23%	+$25.3K	﹤0.01%	2064
2022 Q1	$143K	Buy	+3,782	New	+$149K	﹤0.01%	2065

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Amalgamated Bank's RXDX Position: Q2 2023 in Review

Amalgamated Bank sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 4,917 shares — an estimated $528K sold.

Amalgamated Bank first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $630K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Amalgamated Bank reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Amalgamated Bank sold 4,917 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $528K.
Amalgamated Bank first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Amalgamated Bank's Prometheus Biosciences, Inc. Common Stock position peaked at $630K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.